



ASX Announcement

7 January 2021

Updated timeline to Phase IIb results

MELBOURNE, AUSTRALIA (7 January 2021): Hexima Limited (ASX:HXL) a clinical stage biotechnology company developing HXP124, a new prescription treatment for onychomycosis, today announces an updated timeline to delivery of results from its phase IIb clinical trial which is being conducted in patients with onychomycosis.

The pace of enrolment of patients into the trial, which is being conducted in Australia and New Zealand, has been modestly impacted by State travel restrictions, business closures and mandated lock downs due to the Coronavirus pandemic. These events have not affected in any way the integrity of the trial but are likely to result in data from the clinical trial being available one calendar quarter later than previously anticipated.

Hexima has recently added additional clinical investigator sites and adopted other measures to accelerate patient recruitment and enrolment. Accordingly, Hexima expects to announce results of its phase IIb clinical trial of HXP124 in patients with onychomycosis in the second quarter of 2022.

About Hexima

Hexima is a biotechnology company engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics. Its lead product candidate, HXP124 applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial of HXP124 for onychomycosis. Hexima holds granted, long-life patents protecting HXP124 in major markets globally. For additional information about Hexima please visit www.hexima.com.au.

This announcement is authorised for release to ASX by Michael Aldridge, Chief Executive Officer.

Enquiries:

Dr Nicole van der Weerden
Chief Operating Officer
n.vanderweerden@hexima.com.au

Join our email database to receive company announcements:

Info@hexima.com.au
www.hexima.com.au